Bio-Gate wins funding project for antimicrobial HyProtectTM-coated revision hip endoprostheses
Cooperation with Peter Brehm GmbH and the University Hospital Ulm
Nuremberg (Germany), July 31st, 2017 – Bio-Gate AG (ISIN DE000BGAG981) is a leading provider of antimicrobial products and multifunctional surface coatings for the medical device industry. Bio-Gate has once again been awarded another government funding project. In collaboration with the German medical technology company Peter Brehm GmbH (Weisendorf/Bavaria) and the Institute of Orthopaedic Research and Biomechanics at the Center for Trauma Research at the University of Ulm (ZTF) Bio-Gate will jointly conduct a preclinical animal study to examine the application of the antimicrobial HyProtectTM -coating on artificial implants.
The focus of this project is on revision hip endoprostheses. These are used, when a joint prosthesis must be replaced, for example, after loosening of the implant or due to an infection. The Bio-Gate HyProtectTM-coating can help to reduce the bacterial colonization on the implant surface, and thereby reduces the potential risk for reinfections. This coating has already been successfully used for several years in veterinary medicine.
The Bavarian Ministry of Economic Affairs is promoting and supporting the cooperation between all three partners with a high six-figure EURO amount. Due to the cooperation with Peter Brehm GmbH, one of the market leaders in this field, and the renowned University of Ulm, Bio-Gate anticipates an accelerated market entry for the HyProtectTM-coating. The project will run until 2019. The aim is to demonstrate in an animal study, that HyProtect™-coated implants exhibit excellent osseointegration under mechanical load without any restrictions. The generated data will be used during the regulatory product approval process. Once approved, the products of Peter Brehm GmbH will be offered with Bio-Gate’s HyProtect™ coating.
Marc Lloret-Grau, CEO of Bio-Gate AG: „This project will enable us to apply our HyProtect™ coating to additional endoprosthetic products and further our collaborations with other renowned partners and ultimately allow us to expand our market.”
WMP Finanzkommunikation GmbH
Volker Siegert / Christian Dose
Tel: +49 (0)69 / 57 70 300 – 0
Bio-Gate AG is a medical technology company that develops and markets applications which use unique silver technologies to help prevent infections and thus to improve health. Bio-Gate AG’s specialty is using pure silver to treat materials and surfaces that are used in all areas of daily life – providing long-term and medically effective protection against bacteria, microorganisms and other pathogens. Bio-Gate AG concentrates in three fields to supply a variety of products that provide antimicrobial protection: specialized medical surface coatings, enhancement of materials with additives, and the testing and validation of antimicrobial or anti-adhesive materials. The Nuremberg-based company offers systems that stretch across the entire value chain, from product development to production approval. For more information, please visit www.bio-gate.de.
This publication constitutes neither an offer to sell nor an invitation to buy securities. The shares in Bio-Gate AG (the “Shares”) may not be offered or sold in the United States or to or for the account or benefit of “U.S. persons” (as such term is defined in Regulation S under the U.S. Securities Act of 1933, as amended (the “Securities Act”)). The securities have already been sold.